Omega Therapeutics Inc
NASDAQ:OMGA
Intrinsic Value
Omega Therapeutics, Inc. engages in the development of DNA-sequence-targeting, mRNA-encoded therapeutics. [ Read More ]
The intrinsic value of one OMGA stock under the Base Case scenario is 0.43 USD. Compared to the current market price of 3.65 USD, Omega Therapeutics Inc is Overvalued by 88%.
Valuation Backtest
Omega Therapeutics Inc
Run backtest to discover the historical profit from buying and selling OMGA stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Omega Therapeutics Inc
Current Assets | 101.9m |
Cash & Short-Term Investments | 89.3m |
Receivables | 1.4m |
Other Current Assets | 11.2m |
Non-Current Assets | 115.9m |
PP&E | 115.5m |
Other Non-Current Assets | 400k |
Current Liabilities | 26.8m |
Accounts Payable | 2.4m |
Accrued Liabilities | 19.3m |
Other Current Liabilities | 5.1m |
Non-Current Liabilities | 115m |
Long-Term Debt | 15.9m |
Other Non-Current Liabilities | 99.1m |
Earnings Waterfall
Omega Therapeutics Inc
Revenue
|
2.9m
USD
|
Operating Expenses
|
-113.4m
USD
|
Operating Income
|
-110.5m
USD
|
Other Expenses
|
2.5m
USD
|
Net Income
|
-108.1m
USD
|
Free Cash Flow Analysis
Omega Therapeutics Inc
What is Free Cash Flow?
OMGA Profitability Score
Profitability Due Diligence
Omega Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
Omega Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
OMGA Solvency Score
Solvency Due Diligence
Omega Therapeutics Inc's solvency score is 49/100. The higher the solvency score, the more solvent the company is.
Score
Omega Therapeutics Inc's solvency score is 49/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
OMGA Price Targets Summary
Omega Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for OMGA is 12.24 USD with a low forecast of 10.1 USD and a high forecast of 15.75 USD.
Ownership
OMGA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
OMGA Price
Omega Therapeutics Inc
Average Annual Return | -39.12% |
Standard Deviation of Annual Returns | 25.22% |
Max Drawdown | -95% |
Market Capitalization | 201.1m USD |
Shares Outstanding | 55 141 800 |
Percentage of Shares Shorted | 19.12% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Omega Therapeutics, Inc. engages in the development of DNA-sequence-targeting, mRNA-encoded therapeutics. The company is headquartered in Cambridge, Massachusetts. The company went IPO on 2021-07-30. The firm is engaged in a systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming platform. Its OMEGA Epigenomic Programming platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism's life from cell genesis, growth, and differentiation to cell death. The company has deciphered the three-dimensional architecture of the human genome and its accompanying regulators, which are organized into distinct and evolutionarily conserved structures called Insulated Genomic Domains (IGDs). The OMEGA platform enables to systematically identify and validate thousands of DNA-sequence-based epigenomic zip codes within IGDs. Its pipeline consists of early-stage, preclinical programs that span regenerative medicine, multigenic diseases including immunology, oncology, and select monogenic diseases.
Contact
IPO
Employees
Officers
The intrinsic value of one OMGA stock under the Base Case scenario is 0.43 USD.
Compared to the current market price of 3.65 USD, Omega Therapeutics Inc is Overvalued by 88%.